Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation

Transplantation

Volumn 64, Issue 9, 1997, Pages 1248-1255

  Naka, Yoshifumi ^a   Marsh, Henry C ^b   Scesney, Susanne M ^b   Oz, Mehmet C ^a   Pinsky, David J ^a,c  

^a Columbia University ^*  (United States)

^b T Cell Sciences Inc   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPLEMENT ACTIVATION; ENZYME ACTIVITY; GRAFT FAILURE; HEMOLYSIS; IMMUNOHISTOCHEMISTRY; ISOGRAFT; LUNG ARTERY; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NONHUMAN; ORGAN PRESERVATION; PRIORITY JOURNAL; RAT; XENOGRAFT;

ANIMALS; COMPLEMENT ACTIVATION; GRAFT REJECTION; HYPOTHERMIA, INDUCED; LUNG; LUNG TRANSPLANTATION; MALE; ORGAN PRESERVATION; PULMONARY CIRCULATION; RATS; RATS, INBRED LEW; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030666925     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711150-00004     Document Type: Article

References (51)

1. Pinckard RN, O'Rourke RA, Crawford MH, et al. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 1980; 66: 1050.
2. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted area of human myocardium. J Immunol 1986; 137: 1945.
3. Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation 1990; 81: 156.
4. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264: 1.
5. Stimler NP, Hugli TE, Bloor CM. Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol 1980; 100: 327.
6. Marder SR, Chenoweth DE, Goldstein IM, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 1985; 134: 3325.
7. Till GO, Johnson KJ, Kunkel R, Ward PA. Intravascular activation of complement and acute lung injury: dependency on neutrophils and toxic oxygen metabolites. J Clin Invest 1982; 69: 1126.
8. Till GO, Morganroth ML, Kunkel R, Ward PA. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol 1987: 129: 44.
9. Maroko PR, Carpenter CB, Chiariello M, et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 1978; 61: 661.
10. Crawford MH, Grover FL, Kolb WP, et al. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988; 78: 1449.
11. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
12. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppression post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
13. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979; 76: 5867.
14. Medof ME, Iida K, Mold C, Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982; 156: 1739.
15. Ross GD. Complement receptor type 1. Curr Topics Microbiol Immunol 1992; 178: 31.
16. Shandelya SML, Kuppusamy P, Herskowitz A, Weisfeldt M, Zweier JL. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart: evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation 1993; 88: 2812.
17. Chaves-Cartaya RE, DeSola GP, Wright L, Jamieson NV. Regulation of the complement cascade by soluble complement receptor type 1: protective effect in experimental liver ischemia and reperfusion. Transplantation 1995; 59: 1047.
18. Lindsay TF, Hill J, Ortiz F, et al. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surg 1992; 216: 677.
19. Pemberton M, Anderson G, Vetvicka V, Justus DE, Ross GD. Microvascular effects of complement blockade with soluble recombinant CRI on ischemia/reperfusion injury of skeletal muscle. J Immunol 1993; 150: 5104.
20. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechman HB, Moore FD. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 1992; 149: 1723.
21. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991; 50: 350.
22. Pruitt SK, Baldwin WM III, Marsh HC Jr, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868.
23. Chowdhury NC, Naka Y, Pinsky DJ, et al. Novel technique of orthotopic lung transplantation in rats in which survival and hemodynamic assessment can be measured independent of the native lung. Surg Forum 1994; 45: 268.
24. Goldblum SE, Wu K-M, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1978; 59: 1978.
25. Mayer MM. Complement and complement fixation. In: Kabat EA, ed. Experimental immunochemistry. Springfield, IL: Thomas, 1961: 113.
26. Platts-Mills TAE, Ishizaka K. Activation of the alternate pathway of human complement by rabbit cells. J Immunol 1974; 113: 348.
27. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC. C5a decreases regional coronary blood flow and myocardial function in pigs: implications for granulocyte mechanism. Circ Res 1988; 63: 483.
28. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial ischemia: role for CD18-dependent PMN localization and PMN-platelet interactions. Am J Physiol 1993; 265: H1750.
29. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit: evidence for a role for C5a and interleukin-8. J Clin Invest 1995; 95: 2720.
30. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate xenografts from humoral injury. Nat Med 1995; 1: 423.
31. Pinsky DJ, Naka Y, Chowdhury NC, et al. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci USA 1994; 91: 12086.
32. Naka Y, Chowdhury NC, Liao H, et al. Enhanced preservation of orthotopically transplanted rat lungs by nitroglycerin but not hydralazine: requirement for graft vascular homeostasis beyond harvest vasodilation. Circ Res 1995; 76: 900.
33. Hall TS, Breda MA, Baumgartner WA, et al. The role of leukocyte depletion in reducing injury to the lung after hypothermie ischemia. Curr Surg 1987; 44: 137.
34. Pillai R, Bando K, Schueler S, Zebley M, Reitz BA, Baumgartner WA. Leukocyte depletion results in excellent heart-lung function after 12 hours of storage. Ann Thorac Surg 1990; 50: 211.
35. Mathey D, Schofer J, Schafer HJ, et al. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994; 15: 418.
36. Rossen RD, Michael LH, Kagiyama A, et al. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res 1988; 62: 572.
37. Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RD. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human C1q and fix complement. Circ Res 1989; 64: 607.
38. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981; 1: 165.
39. Vakeva A, Laurila R, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 1992; 67: 608.
40. Yoon SH, Fearon DT. Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 1985; 134: 3332.
41. Stahl GL, Reenstra WR, Frendl G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries: role of the terminal membrane attack complex. Circ Res 1995; 76: 575.
42. Fearon DT, Wong WW. Complement ligand-receptor interaction that mediate biological response. Annu Rev Immunol 1983; 1: 243.
43. Shandelya SM, Kuppusamy P, Weisfeldt ML, Zweier JL. Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury: evidence for plasma-mediated leukocyte activation. Circulation 1993; 87: 536.
44. Naka Y, Stern DM, Pinsky DJ. The pathophysiology and biochemistry of myocardial ischemia, necrosis, and reperfusion. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven Publishers, 1996: 807.
45. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart: role of the terminal complement components. Circ Res 1992; 71: 303.
46. Berger HJ, Taratuska A, Smith TW, Halperin JA. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Am J Physiol 1993; 265: H267.
47. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol 1993; 143: 65.
48. 2+-initiated activation of cellular protein kinase. J Biol Chem 1987; 262: 13674.
49. Hattori R, Hamilton KK, McEverf RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053.
50. Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA. Neutrophil-dependent acute lung injury: requirement for P-selectin (GMP-140). J Clin Invest 1992; 90: 1600.
51. Naka Y, Toda K, Kayano K, Oz MC, Pinsky DJ. Failure to express the P-selectin gene or P-selectin blockade confer early pulmonary protection after lung ischemia or transplantation. Proc Natl Acad Sci USA 1997; 94: 757.